Table 5.
Levels of 6-sulphatoxymelatonin and zinc of the study participants who completed the final assessment.
| Melatonin (as aMT6s), ng/mL urine |
Placebo (n = 26) |
Mel-Zinc (n = 24) |
p-Value 1 |
|---|---|---|---|
| Baseline | 16.55 ± 2.39 | 24.91 ± 3.43 | 0.063 |
| 8 weeks | 16.68 ± 2.44 | 283.50 ± 8.47 *** | <0.0001 |
| 16 weeks | 14.85 ± 2.14 | 284.20 ± 8.45 *** | <0.0001 |
| 4 weeks after treatment | 13.21 ± 2.18 | 26.45 ± 5.61 *** | 0.078 |
| Zinc, µg/dL |
Placebo
(n = 26) |
Mel-Zinc
(n = 24) |
p -Value 1 |
| Baseline | 114.73 ± 3.94 | 122.04 ± 6.34 | 0.676 |
| 8 weeks | 114.42 ± 4.26 | 120.96 ± 4.92 | 0.336 |
| 16 weeks | 126.62 ± 4.74 | 129.21 ± 6.28 | 0.641 |
| 4 weeks after treatment | 121.45 ± 3.18 | 127.87 ± 5.18 | 0.735 |
Data are expressed as the mean ± SEM and compared by a paired Student’s t-test, where appropriate, for intragroup analysis, and by a Wilcoxon’s signed rank test for between-group analysis. The significance threshold was set at *** p < 0.001. Abbreviations: Mel-Zinc, melatonin plus zinc group. 1 p-values for between-group analysis.